List of Juno Therapeutics patents

Patents where

Current Assignee

Name

Juno Therapeutics

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 11866465 Oligomeric particle reagents and methods of use thereof	Patent 11866465 was granted and assigned to Juno Therapeutics on January, 2024 by the United States Patent and Trademark Office.	Juno Therapeutics	Juno Therapeutics	United States Patent and Trademark Office	11866465	January 9, 2024
‌ US Patent 11913024 Methods for culturing cells and kits and apparatus for same	Patent 11913024 was granted and assigned to Juno Therapeutics on February, 2024 by the United States Patent and Trademark Office.	Juno Therapeutics	Juno Therapeutics	United States Patent and Trademark Office	11913024	February 27, 2024
‌ US Patent 11020429 Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy	Patent 11020429 was granted and assigned to Juno Therapeutics on June, 2021 by the United States Patent and Trademark Office.	Juno Therapeutics	Juno Therapeutics	United States Patent and Trademark Office	11020429	June 1, 2021
‌ US Patent 11266739 Methods and compositions for adoptive cell therapy	Patent 11266739 was granted and assigned to Juno Therapeutics on March, 2022 by the United States Patent and Trademark Office.	Juno Therapeutics	Juno Therapeutics	United States Patent and Trademark Office	11266739	March 8, 2022
‌ US Patent 11400115 Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy	Patent 11400115 was granted and assigned to Juno Therapeutics on August, 2022 by the United States Patent and Trademark Office.	Juno Therapeutics	Juno Therapeutics	United States Patent and Trademark Office	11400115	August 2, 2022
‌ US Patent 11633426 Methods and compositions for dosing in adoptive cell therapy	Patent 11633426 was granted and assigned to Juno Therapeutics on April, 2023 by the United States Patent and Trademark Office.	Juno Therapeutics	Juno Therapeutics	United States Patent and Trademark Office	11633426	April 25, 2023
‌ US Patent 10507219 Methods and compositions for dosing in adoptive cell therapy	Patent 10507219 was granted and assigned to Juno Therapeutics on December, 2019 by the United States Patent and Trademark Office.	Juno Therapeutics	Juno Therapeutics	United States Patent and Trademark Office	10507219	December 17, 2019
‌ US Patent 11471489 T cell receptors and engineered cells expressing same	Patent 11471489 was granted and assigned to Juno Therapeutics on October, 2022 by the United States Patent and Trademark Office.	Juno Therapeutics	Juno Therapeutics	United States Patent and Trademark Office	11471489	October 18, 2022
‌ US Patent 11623961 Antibodies and chimeric antigen receptors specific for B-cell maturation antigen	Patent 11623961 was granted and assigned to Juno Therapeutics on April, 2023 by the United States Patent and Trademark Office.	Juno Therapeutics	Juno Therapeutics	United States Patent and Trademark Office	11623961	April 11, 2023
‌ US Patent 11535903 Methods and reagents for assessing the presence or absence of replication competent virus	Patent 11535903 was granted and assigned to Juno Therapeutics on December, 2022 by the United States Patent and Trademark Office.	Juno Therapeutics	Juno Therapeutics	United States Patent and Trademark Office	11535903	December 27, 2022
‌ US Patent 10533055 Antibodies and chimeric antigen receptors specific for CD19	Patent 10533055 was granted and assigned to Juno Therapeutics on January, 2020 by the United States Patent and Trademark Office.	Juno Therapeutics	Juno Therapeutics	United States Patent and Trademark Office	10533055	January 14, 2020
‌ US Patent 11421287 Methods for assessing the presence or absence of replication competent virus		Juno Therapeutics	Juno Therapeutics	United States Patent and Trademark Office	11421287	August 23, 2022
‌ US Patent 10889652 Antibodies and chimeric antigen receptors specific for ROR1	Patent 10889652 was granted and assigned to Juno Therapeutics on January, 2021 by the United States Patent and Trademark Office.	Juno Therapeutics	Juno Therapeutics	United States Patent and Trademark Office	10889652	January 12, 2021
‌ US Patent 10363269 Modified hepatitis post-transcriptional regulatory elements	Patent 10363269 was granted and assigned to Juno Therapeutics on July, 2019 by the United States Patent and Trademark Office.	Juno Therapeutics	Juno Therapeutics	United States Patent and Trademark Office	10363269	July 30, 2019
‌ US Patent 11413310 Articles of manufacture and methods for treatment using adoptive cell therapy	Patent 11413310 was granted and assigned to Juno Therapeutics on August, 2022 by the United States Patent and Trademark Office.	Juno Therapeutics	Juno Therapeutics	United States Patent and Trademark Office	11413310	August 16, 2022
‌ US Patent 11072660 HPV-specific binding molecules	Patent 11072660 was granted and assigned to Juno Therapeutics on July, 2021 by the United States Patent and Trademark Office.	Juno Therapeutics	Juno Therapeutics	United States Patent and Trademark Office	11072660	July 27, 2021
‌ US Patent 11561219 Methods of enumerating particles present in a cell composition		Juno Therapeutics	Juno Therapeutics	United States Patent and Trademark Office	11561219	January 24, 2023
‌ US Patent 10428351 Methods for transduction and cell processing	Patent 10428351 was granted and assigned to Juno Therapeutics on October, 2019 by the United States Patent and Trademark Office.	Juno Therapeutics	Juno Therapeutics	United States Patent and Trademark Office	10428351	October 1, 2019
‌ US Patent 10738278 Engineered cells for adoptive cell therapy		Juno Therapeutics	Juno Therapeutics	United States Patent and Trademark Office	10738278	August 11, 2020
‌ US Patent 10786533 Engineered cells for adoptive cell therapy	Patent 10786533 was granted and assigned to Juno Therapeutics on September, 2020 by the United States Patent and Trademark Office.	Juno Therapeutics	Juno Therapeutics	United States Patent and Trademark Office	10786533	September 29, 2020
‌ US Patent 11802295 Methods for transduction and cell processing	Patent 11802295 was granted and assigned to Juno Therapeutics on October, 2023 by the United States Patent and Trademark Office.	Juno Therapeutics	Juno Therapeutics	United States Patent and Trademark Office	11802295	October 31, 2023
‌ US Patent 11851679 Method of assessing activity of recombinant antigen receptors	Patent 11851679 was granted and assigned to Juno Therapeutics on December, 2023 by the United States Patent and Trademark Office.	Juno Therapeutics	Juno Therapeutics	United States Patent and Trademark Office	11851679	December 26, 2023
‌ US Patent 12006356 Anti-CCT5 binding molecules and chimeric antigen receptors comprising the same	Patent 12006356 was granted and assigned to Juno Therapeutics on June, 2024 by the United States Patent and Trademark Office.	Juno Therapeutics	Juno Therapeutics	United States Patent and Trademark Office	12006356	June 11, 2024
‌ US Patent 11564946 Methods associated with tumor burden for assessing response to a cell therapy	Patent 11564946 was granted and assigned to Juno Therapeutics on January, 2023 by the United States Patent and Trademark Office.	Juno Therapeutics	Juno Therapeutics	United States Patent and Trademark Office	11564946	January 31, 2023
‌ US Patent 11944647 Articles of manufacture and methods for treatment using adoptive cell therapy	Patent 11944647 was granted and assigned to Juno Therapeutics on April, 2024 by the United States Patent and Trademark Office.	Juno Therapeutics	Juno Therapeutics	United States Patent and Trademark Office	11944647	April 2, 2024

Results per page:

28 results

0 selected

28 results

0 selected